IR@PKUHSC  > 北京大学临床研究所
学科主题临床医学
Factors associated with compliance to lipid-lowering treatment in China
Xie, Gaoqiang1; Zaman, M. Justin S.2,3,4; Myint, Phyo K.4,5; Liang, Lirong6; Zhao, Liancheng7,8; Wu, Yangfeng1,9
关键词Compliance Dyslipidaemia Lipid-lowering Therapy Cardiovascular Disease
刊名EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
2013-04-01
DOI10.1177/2047487312438847
20期:2页:229-237
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]CORONARY-HEART-DISEASE ; TREATMENT PANEL-III ; CHOLESTEROL LEVELS ; STATIN THERAPY ; POPULATION ; PREVENTION ; ADHERENCE ; EDUCATION ; HEALTH ; DYSLIPIDEMIA
英文摘要

Background: There are an estimated 200 million people in China with dyslipidaemia. We sought to explore factors that influence compliance to treatment of dyslipidaemia, using a multi-centre sample in China.

Methods: Through review of medical notes and direct interviews at two points in time (2006 and 2007) of 2094 patients in 27 hospitals receiving lipid-lowering therapy since 2004, 1890 patients were recruited who had been on treatment for more than one year. Good compliance (GC) was defined as days taking lipid-lowering drugs/total days of follow-up >= 80%. Logistic regression models were used to assess factors associated with GC.

Results: In patients with one, two and three years of treatment respectively, GC was greater in those with higher versus lower medical insurance cover - odds ratios 2.8 (95%CI 2.2-3.7), 2.0 (1.5-2.7), 4.3 (2.3-8.1); in patients in province-level versus county-level hospitals-2.0 (1.5-2.6), 2.9 (2.0-4.1), 4.6 (1.8-12.0); in patients treated by non-cardiology physicians compared to cardiologists -1.7 (1.1-2.5), 2.0 (1.3-3.0), 4.0 (1.5-10.3) and in patients using a statin versus other forms of medication for dyslipidaemia -1.7 (1.2-2.2), 1.7 (1.2-2.3), 4.4 (2.3-8.5).

Conclusions: Better medical insurance cover, care in a province-level hospital rather than county-level hospital, treatment by a non-cardiologist and use of a statin were associated with better compliance to lipid-lowering treatment.

语种英语
WOS记录号WOS:000318876700005
资助机构Schering-Plough China Corp ; Merck Sharp &amp ; Dohme China Corp
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50837
专题北京大学临床研究所
作者单位1.James Paget Univ Hosp, Dept Cardiol, Great Yarmouth, England
2.George Inst, Beijing, Peoples R China
3.Peking Univ, Clin Res Inst, Beijing 100871, Peoples R China
4.George Inst Global Hlth, Div Cardiovasc, Sydney, NSW, Australia
5.Univ E Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England
6.Univ Cambridge, Dept Publ Hlth & Primary Care, Clin Gerontol Unit, Cambridge, England
7.Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
8.Peking Union Med Coll, Fuwai Hosp, Beijing 100021, Peoples R China
9.Chinese Acad Med Sci, Beijing 100730, Peoples R China
推荐引用方式
GB/T 7714
Xie, Gaoqiang,Zaman, M. Justin S.,Myint, Phyo K.,et al. Factors associated with compliance to lipid-lowering treatment in China[J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY,2013,20(2):229-237.
APA Xie, Gaoqiang,Zaman, M. Justin S.,Myint, Phyo K.,Liang, Lirong,Zhao, Liancheng,&Wu, Yangfeng.(2013).Factors associated with compliance to lipid-lowering treatment in China.EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY,20(2),229-237.
MLA Xie, Gaoqiang,et al."Factors associated with compliance to lipid-lowering treatment in China".EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 20.2(2013):229-237.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xie, Gaoqiang]的文章
[Zaman, M. Justin S.]的文章
[Myint, Phyo K.]的文章
百度学术
百度学术中相似的文章
[Xie, Gaoqiang]的文章
[Zaman, M. Justin S.]的文章
[Myint, Phyo K.]的文章
必应学术
必应学术中相似的文章
[Xie, Gaoqiang]的文章
[Zaman, M. Justin S.]的文章
[Myint, Phyo K.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。